Incyte retires $212.3 million of two series of 3.5% convertible notes

By Jennifer Chiou

New York, Nov. 5 - Incyte Corp. announced in its third-quarter report that it retired $86.3 million of its 3.5% convertible senior notes due 2011 and $99.9 million of its 3.5% convertible subordinated notes due 2011.

Incyte used $183.8 million of the $388 million of net proceeds from a private placement of 4.75% convertible senior notes due 2015 as well as the $132.7 million of net proceeds from a follow-on equity financing of 20.7 million shares.

Through Nov. 4, the company retired an additional $26.1 million of the subordinated notes.

"We recently raised over $500 million in our common stock and senior convertible notes offerings, which we intend to use to complete the phase III program for our lead JAK½ inhibitor, INCB18424, for myelofibrosis, advance our pipeline, and reduce our existing convertible notes that are due in 2011," Paul A. Friedman, president and chief executive officer, said in a news release.

"Thus far, we have retired over $212 million of the $400 million outstanding principal balance."

The Wilmington, Del.-based drug discovery and development company is focused on proprietary small molecule drugs for oncology, inflammation and diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.